WaferGen Bio-systems, Inc. (WGBS)

WaferGen

CEO: Carol Lou

Headquarters: Shiga, Japan

URL: www.takara-bio.com

Investment Date: May 2007

Initial Funding: $12,012,000 (Acquired in March 2017 for $35.9 Million by Takara BIO USA Holdings, Inc.)

Trading Venue: Acquired

WaferGen Biosystems, Inc. is an emerging leader in the development, manufacture, and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker identification and validation.

The clinical sequencing community has been challenged with the transfer of next gen sequencing tests from research and development into the clinic. To meet this challenge WaferGen has developed the high-density SmartChip TE System for targeted sequencing. Practical benefits of this target enrichment methodology include flexibility in CLIA sequencing panel development, improved accuracy and precision with a simple, intuitive, lab-friendly workflow in target sequencing protocols. We currently have access to assay designs for the whole human exome facilitating rapid development of amplicon sequencing panels.

WaferGen Bio-systems

DISCLAIMER

This website and the information herein is proprietary and confidential and is being presented by Montrose Capital Partners and its affiliates and subsidiaries (“Montrose”) to provide an overview of the Montrose business operations, capabilities and related products/services. You agree to treat this information, including information about possible future transactions, transaction structures and their terms, in strict confidence, not to disclose such information to any other party and not to use such information for any purpose other than in evaluating an interest, if any, in the proposed transactions.

This website was prepared by Montrose for illustration and informational purposes only, and should not be construed as a solicitation to effect, attempt to effect, either transactions in securities or the rendering of personalized investment advice. This website is not to be construed as a recommendation or an offer to sell or a solicitation of an offer to buy securities. Any opinions or comments expressed herein are not necessarily representative of the opinions and views of Montrose or its management, employees, agents or other representatives. Any views, opinions and advice provided in this website has been prepared without taking into account the investment objectives, financial objectives, situation or specific needs of any individual person. Certain information in this website has been derived from publicly available sources that we believe to be accurate; however, we have not verified such information and no rewebsite or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information or opinions and conclusions, if any, in this website. No rewebsite is being made that any investment undertaken, will or is likely to achieve profits or avoid substantial losses. There is a risk of substantial loss in all transactions. To the maximum extent permitted by law, neither Montrose or its management, employees, agents or any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this website.

Any dissemination, distribution or reproduction of this website is strictly prohibited without the consent of Montrose. No part of this website may be reproduced, stored, or transmitted by any means without the express written consent of Montrose. All brands, company names, and product names are trademarks or registered trademarks of their respective holder.

© 2017 Montrose Partners. All rights reserved.

Agree